Advertisement

Topics

De Novo Pharmaceuticals Company Profile

04:27 EST 22nd November 2017 | BioPortfolio

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment round in April 2000, followed by a second round of funding of £16.75 million in July 2001. Investors in the first round included Avlar Bioventures, Prelude Technology and Cambridge Research and Innovation Limited. Second round investors included Merlin Bioventures, Life Science Partners NV, Quester and FNI Venture Capital, as well as the industrial investors Roche and Incyte Pharmaceuticals. De Novo has already announced Drug Design Partnerships with 3 major pharmaceutical companies (Aventis, British Biotechnology and Organon), and 2 Technology Development Partnerships (with Roche and Sun Microsystems). With new facilities at Vision Park in Histon, the company is currently building a “gene-to-drug” pipeline of its own.

Location

St Andrews House, 59 St Andrews St
Cambridge
Cambridgeshire
CB2 3DD
United Kingdom

Contact

Phone: 01223 331984
Fax: 01223 327192
Email: anthony.williams@denovopharma.com


News Articles [895 Associated News Articles listed on BioPortfolio]

Novo Nordisk A/S: Changes in Novo Nordisk Executive Management

Bagsværd, Denmark, 15 August 2017 - Novo Nordisk A/S today announced two changes to its Executive Management team. As of 1 October, Camilla Sylvest, senior vice president in charge of Novo Nordisk...

Novo Nordisk-Aktie: Positiver Newsflow ebbt nicht ab!

Liebe Leser, mit den positiven Nachrichten rund um das Pharmaunternehmen Novo Nordisk geht es weiter. Durch die Empfehlung eines Ausschusses der US-Zulassungsbehörde FDA für das von Novo Nordisk en....

Novo Nordisk hebt Jahresprognose an

Von Dominic Chopping STOCKHOLM (Dow Jones)--Der dänische Pharmakonzern Novo Nordisk hat seine Prognose für dieses Jahr angehoben. Die Novo Nordisk A/S rechnet mit robusten Umsätzen mit ihren Diabe....

Novo Nordisk: Wichtige Neuigkeiten aus den USA

Erfolg für den Insulinhersteller Novo Nordisk in den USA: 2018 bleiben wichtige Novo-Produkte auf der Einkaufsliste der Einkaufsorganisation CVS Health. Der Verbleib auf der Liste sichert den Dänen....

Deals this week: Milestone Pharmaceuticals, Homology Medicines, Ultragenyx Pharmaceutical

Canadian cardiovascular drug development company Milestone Pharmaceuticals has secured $55m through a series C funding round led by Novo Holdings.

FDA Committee Votes 16-0 for Approval of Novo Nordisk Diabetes Treatment

NewsNovo Nordisk receives positive 16-0 vote from FDA advisory committee in favor of approval for semaglutide. The treatment is currently also under review by the European Medicines Agency and the Jap...

Novo Nordisk: Aktie mit Kurssprung - was ist da los?

Große Freude bei den Aktionären von Novo Nordisk und auch von BB Biotech, in deren Portfolio die Aktie der Dänen mit einem Anteil von 4,0 Prozent Platz 10 einnimmt. Die Aktie von Novo Nordisk gewin...

Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

Sanofi and Novo Nordisk this morning have put their venture arms to work. The two joined up with two venture firms to back a $49 million round for a fledgling startup, Inozyme Pharmaceuticals. The com...

Drugs and Medications [296 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Myfortic [Novartis Pharmaceuticals Corporation]

Myfortic (mycophenolic   acid*) delayed-release tablets *as mycophenolate   sodium Rx only Prescribing Information

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

PubMed Articles [407 Associated PubMed Articles listed on BioPortfolio]

Terasaki epitope mismatch burden predicts the development of de novo DQ donor specific antibodies and are associated with adverse allograft outcomes.

De novo DQ DSA are associated with antibody-mediated rejection and allograft loss. Given the lack of effective treatment of de novo DQ DSA, their prevention is vital if there is to be an improvement o...

De Novo Cavernous Angioma Secondary to a Developmental Venous Anomaly:A Case Report and Review of the Literature.

Previously, cavernous angiomas(CAs)have been thought to be only congenital in origin. Recently, however, a few cases of de novo CAs have been reported in the literature. We present a case of a de novo...

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Clinical Trials [532 Associated Clinical Trials listed on BioPortfolio]

Evaluating Therapeutic Response to Novo-TTF

This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1332 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment roun...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

NOVO Engineering

NOVO engineering (www.NOVOengineering.com) is a leading privately held design engineering firm whose team of world-class engineers has been exceeding clients’ needs since 199...

More Information about "De Novo Pharmaceuticals" on BioPortfolio

We have published hundreds of De Novo Pharmaceuticals news stories on BioPortfolio along with dozens of De Novo Pharmaceuticals Clinical Trials and PubMed Articles about De Novo Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of De Novo Pharmaceuticals Companies in our database. You can also find out about relevant De Novo Pharmaceuticals Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record